首页> 外文OA文献 >Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
【2h】

Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients

机译:孟鲁司特辅助治疗老年哮喘的安全性和有效性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientific biases. A large body of evidence has accumulated in recent years to confirm that the prevalence of asthma in the most advanced ages is similar to that in younger ages. Asthma in the elderly may show similar functional and clinical characteristics to that occurring in young adults, although the frequent coexistence of comorbid conditions in older patients, together with age-associated changes in the human lung, may lead to more severe forms of the disease. Management of asthma in the elderly follows specific guidelines that apply to all ages, although most behaviors are pure extrapolation of what has been tested in young ages. In fact, age has always represented an exclusion criterion for eligibility to clinical trials. This review focuses specifically on the safety and efficacy of leukotriene modifiers, which represent a valid option in the treatment of allergic asthma, both as an alternative to first-line drugs and as add-on treatment to inhaled corticosteroids. Available studies specifically addressing the role of montelukast in the elderly are scarce; however, leukotriene modifiers have been demonstrated to be safe in this age group, even though cases of acute hepatitis and occurrence of Churg-Strauss syndrome have been described in elderly patients; whether this is associated with age is to be confirmed. Furthermore, leukotriene modifiers provide additional benefit when added to regular maintenance therapy, not differently from young asthmatics. In elderly patients, the simpler route of administration of leukotriene modifiers, compared with the inhaled agents, could represent a more effective strategy in improving the outcomes of asthma therapy, given that unintentional nonadherence with inhalation therapy represents a complex problem that may lead to significant impairment of asthma symptom control.
机译:哮喘是所有年龄段的疾病。由于多种文化和科学偏见,过去一直对此假设提出质疑。近年来,已经积累了大量的证据,以确认最年老的哮喘患病率与年轻的年龄相似。老年人的哮喘可能表现出与年轻人相似的功能和临床特征,尽管老年患者并存疾病的频繁并存以及人类肺部与年龄相关的变化可能导致该疾病的更严重形式。老年人的哮喘治疗遵循适用于所有年龄段的特定指南,尽管大多数行为纯属外来年龄的测试。实际上,年龄始终代表有资格参加临床试验的排除标准。这篇综述特别侧重于白三烯修饰剂的安全性和有效性,白三烯修饰剂是治疗过敏性哮喘的有效选择,既可以替代一线药物,也可以作为吸入性糖皮质激素的附加治疗。很少有专门研究孟鲁司特在老年人中的作用的研究。然而,尽管已报道老年患者患有急性肝炎和发生Churg-Strauss综合征,但在该年龄组中白三烯修饰剂已被证明是安全的。是否与年龄有关尚待确认。此外,白三烯修饰剂在添加到常规维持疗法中时可提供额外的益处,与年轻的哮喘病患者并无不同。在老年患者中,与吸入剂相比,白三烯修饰剂的更简单给药途径可能代表改善哮喘治疗结果的更有效策略,因为吸入治疗的无意不依从是一个复杂的问题,可能导致严重的损害控制哮喘症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号